United Therapeutics Corp

2026-09-11 22:11; UTC

United Therapeutics shares traded roughly flat in after-market hours. The stock remains below its 20-day moving average amid recent lower closes.

2026-09-10 20:07; UTC

United Therapeutics Corp shares are lower today amid broader market declines influenced by rising Treasury yields and the European Central Bank's interest rate hike.

2026-09-09 19:36; UTC

United Therapeutics Corp shares are higher today, reaching a peak return. This movement occurs amid rising crude oil prices and inflation concerns.

2026-09-08 22:36; UTC

United Therapeutics Corp shares declined in after-market trading, following CEO Martine Rothblatt's sale of 9,500 shares valued at $4.65 million.

2026-09-03 19:56; UTC

United Therapeutics Corp's stock is trading lower, pressured despite FDA acceptance of its new drug application, reaching a 52-week low of $375.61.

2026-09-02 20:02; UTC

United Therapeutics Corp shares are declining amid concerns over insider selling by CEO Martine Rothblatt, despite positive FDA news on Tyvaso.

2026-09-01 20:08; UTC

United Therapeutics Corp shares are higher, supported by the Biotechnology sector's advance and upcoming investor conferences aimed at boosting market visibility.

2026-08-31 22:01; UTC

The FDA accepted United Therapeutics' New Drug Application for ralinepag, aimed at treating pulmonary arterial hypertension, boosting shares modestly higher in after-market hours.

2026-08-28 21:02; UTC

United Therapeutics shares are higher in after-market trading, recovering from a brief low earlier. Broader inflation discussions continue, with no specific company news identified.

2026-08-27 20:01; UTC

United Therapeutics shares are trading higher as CEO Martine Rothblatt exercised an option for 9,500 shares at $135.42. The stock remains above its 20-day moving average.

2026-08-26 19:46; UTC

United Therapeutics shares are lower as CEO Martine Rothblatt exercised an option for 9,500 shares at $135.42, raising potential supply concerns.

2026-08-25 23:26; UTC

United Therapeutics Corp. shares are trading roughly flat in after-market hours, reflecting routine performance and remaining near the middle of their one-month trading range.

2026-08-24 21:01; UTC

United Therapeutics shares lower in after-market hours following FDA acceptance of ralinepag's New Drug Application for pulmonary arterial hypertension.

2026-08-21 19:46; UTC

United Therapeutics Corp shares are lower amid rising U.S. Treasury yields, which have heightened concerns about inflation and government debt levels.

2026-08-20 23:16; UTC

Shares of United Therapeutics Corp are trading higher in after-market hours, despite routine fluctuations and a decrease from an earlier high.

2026-08-19 22:02; UTC

United Therapeutics Corp. shares declined in after-market trading, reversing gains from the previous three sessions. No specific news was identified to explain the drop.

2026-08-18 19:11; UTC

United Therapeutics shares are higher, supported by insider activity and full enrollment in the TETON-PPF study evaluating Tyvaso for pulmonary fibrosis.

2026-08-17 19:46; UTC

United Therapeutics Corp completed enrollment in its Phase 3 TETON-PPF study for Tyvaso, and shares are advancing during Monday's session, despite a pullback earlier.

2026-08-13 19:51; UTC

United Therapeutics Corp shares are lower today, breaking a trend of higher closes. No specific news was identified to explain the decline.

2026-08-12 23:01; UTC

United Therapeutics Corp shares are higher in after-market trading, supported by easing concerns over Federal Reserve rate hikes amid rising consumer prices.

2026-08-11 23:02; UTC

United Therapeutics Corp is trading lower in after-market hours, continuing a trend of three consecutive daily declines without any specific news driving the movement.

2026-08-10 20:06; UTC

United Therapeutics Corp shares are lower during Monday's session, with no specific news identified to explain the decline amid broader market volatility.

2026-08-07 19:51; UTC

United Therapeutics Corp shares are higher, driven by positive sentiment from significant insider transactions and strong investor interest amid a rising Biotechnology sector.

2026-08-06 23:01; UTC

United Therapeutics Corp. shares are higher in after-market trading, continuing a steady increase since Thursday's close and remaining above the 20-day moving average.

2026-08-05 20:02; UTC

United Therapeutics reported second-quarter revenues of $783.3 million, missing estimates of $805.6 million, while EPS of $7.27 exceeded expectations by $0.18.

2026-08-04 23:51; UTC

Shares of United Therapeutics Corp. are lower in after-market hours, remaining below the 20-day moving average and near the lower end of their one-month trading range.

2026-08-03 19:16; UTC

Shares of United Therapeutics Corp are lower today, trading near the lower end of their one-month range amid a broader market rally in other sectors.

2026-07-30 14:36; UTC

United Therapeutics shares are higher following the publication of full ADVANCE OUTCOMES study results in The Lancet, pending FDA approval for ralinepag.

2026-07-29 20:51; UTC

United Therapeutics shares are higher in after-market trading following The Lancet's publication of results from the ADVANCE OUTCOMES study on Ralinepag for PAH.

2026-07-28 18:21; UTC

United Therapeutics Corp. shares are lower today, continuing a decline since Monday's close amid broader market trends and three consecutive sessions of lower finishes.